[Clinical trial of cefoxitin used in the treatment of patients with cholesteatoma undergoing surgical procedures].
Eleven patients with cholesteatoma undergoing surgical procedures were treated with cefoxitin. The following findings were obtained: 1. Eight out of 11 patients' responses were judged "good" and the remaining 3 were judged "fair" with a cure rate of 72.7%. 2. No untoward side effects and abnormalities in laboratory findings were noted on cefoxitin. 3. Cefoxitin should be considered for the treatment of cholesteatoma undergoing surgical procedures because it is well tolerated, has a broad spectrum of antibacterial activity against both Gram-positive and Gram-negative pathogens including anaerobes.
D000293:Adolescent; D000328:Adult; D002440:Cefoxitin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002781:Cholesteatoma / Q000601:surgery*; D004341:Drug Evaluation; D004427:Ear Diseases / Q000601:surgery*; D004432:Ear, Middle; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control; D011292:Premedication; D013530:Surgical Wound Infection / Q000517:prevention & control
D002440:Cefoxitin